Genmab — Marts 2024
-
Biontech hopper tilsvarende
-
Der kan såmænd ikke herske nogen som helst tvivl om, at aktien tog den rette kursretning. Spørgsmålet er kun om timingen er til at det fortsætter umiddelbart. Hvis vi skal forholde os til de “forkætrede” analytikere, var dagen blot et meget lille skridt i den rigtige retning. Vi har fået en bunke nye kursmål, og snittet på de 5 allernyeste er 2937. På de nyeste 10 er det 2820, og 2731 for de sidste 15. Dagen i dag “burde” således kun være en start. Men - hvem tror på analytikere
-
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 https://investors.biontech.de/news/press-releases/
-
Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer.https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-11-2024/card/moderna-biontech-stocks-rise-on-new-mrna-possibilities-S12vWJ4NqDnWylBAbYrb
-
En detalje i Biotech Som man skal bemærke, er at USA 6 marts godkendte lovgivning, der sigter på at forbyde/begrænse kinesiske biotek/medicinalfirmaet i sundhedssektoren. Det medførte et massivt udsalg i kinesiske biotekaktier. Fald på mere end 20% på endag. Måske nogle af de penge, retmæssigt er på vej ind i F.eks Genmab
-
Kan Gmab ikke også få sådan en kommentar i stedet for fokus på omkostninger !!! Kommentar til Biontech opstart af ph 2/3 trial i skin cancer. Jefferies analyst Michael Yee said the initiation of such an expensive trial indicates the companies’ confidence in the program.
-
Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan https://pj.jiho.jp/article/250573 https://genmab.co.jp/wp-content/uploads/2024/03/pressrelease_240311.pdf
-
A bispecific antibody to treat bleeding disorders https://www.nature.com/natcardiovascres/volumes/3/issues/2 // A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders https://www.nature.com/articles/s44161-023-00418-4
-
Hemab Therapeutics
@Hemab_Tx
Preclinical data on HMB-001 in the February 2024 issue of
@NatureCVR
: Let’s take a deep dive to learn what the results show and what it may signal for the future of treatment for bleeding disorders like #GlanzmannThrombasthenia (GT). https://twitter.com/Hemab_Tx/status/1767574739155898493
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind